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Abstract The background of this article is as follows:
Few data are available about the persistence of serum-
specific IgG antibodies to L. infantum after acute VL. The
objective of this article is to evaluate the persistence of
antibodies against L. infantum in patients healed from acute
VL, and the kinetic of the same antibodies observed in 2
cases of VL relapse and 2 cases of resistance to therapy.
The methods which we used to obtain our objective are the
following: 55 apparently immunocompetent, HIV-negative
patients were examined for antibodies to L. infantum by
IFAT over 14 years period, and we got the following
results: Serum-specific IgG antibodies titers decrease
slowly, but constantly. In the patients with a diagnosis of
VL relapse, the kinetic of antibodies was characterized by
an initial reduction, and a subsequent antibody levels rap-
idly increase, while in the patients with a clinical and
parasitological diagnosis of VL not responding to specific
therapy, we demonstrated persistent high level of anti-
bodies to L. infantum. Finally, we conclude that specific
antibodies to L. infantum might persist for many years, and
decrease slowly, but steadily. The persistence of these
specific antibodies is not related to poor therapeutic
response or prognosis, but an acute increase in their levels
might be a sentinel of a VL relapse, while persistence of
high antibody levels could suggest a resistance to therapy.
Keywords Visceral leishmaniasis  L. infantum 
Kinetic of antibodies  Persistence of antibodies 
VL relapse  VL resistance
Abbreviations
VL Visceral leishmaniasis
IFAT Immunofluorescent antibody test
Introduction
Visceral leishmaniasis (VL), caused by Leishmania (L.)
infantum and transmitted to human by the bite of hema-
tophagous sandflies belonging to Phlebotomus spp., is
endemic in areas bordering the Mediterranean sea (Spain,
France, Italy, Greece, Morocco, Tunisia, etc.) [1]. In Italy, in
the years 1996–2005 were reported 1,507 cases, of which
316 (20.9%) (Istituto Nazionale di Statistica, ISTAT, data) in
Sicily [2].
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Diagnosis of VL is carried out on the basis of clinical
signs and symptoms (fever, hepatosplenomegaly, pancy-
topenia, hypergammaglobulinemia, detection of serum
anti-Leishmania antibodies) and/or microscopic detection
of Leishmania promastigotes in Giemsa-stained smears of
bone marrow aspirates and/or biopsy, or lymph node or
spleen aspiration [3].
Methods for detection of parasite-specific antibodies
employ enzyme-linked immunosorbent assay (ELISA),
indirect immunofluorescent antibody test (IFAT), and
Western blotting. Furthermore, Leishmania-specific poly-
merase chain reaction (PCR) of peripheral blood is used to
confirm parasite infection [3]. It is commonly accepted that
it is possible to detect only the presence of serum-specific
IgG antibodies, given that the appearance and disappear-
ance of serum-specific IgM antibodies occurs rapidly,
always before a specific diagnosis of VL could be made
[4–6].
Serological tests may remain positive for long periods of
time, after VL-specific treatment and apparent healing,
although decreases in antibodies titers are evident [7]. In
some studies, the persistence of antibodies for prolonged
periods after treatment appears to indicate a therapeutic
inefficacy or also the possibility of disease reactivation,
while in other reports, there is not any indication of a poor
prognosis and/or a risk of VL relapse [7–13].
In this study, we have analyzed, together with clinical
signs, the persistence of serum IgG antibodies against L.
infantum in sicilian patients with VL, admitted consecu-
tively to our hospital, both cured after acute episode, and
with relapse or resistance to specific therapy.
Materials and methods
Patients
The study was performed in our Dipartimento di Medicina
Clinica e delle Patologie Emergenti, which acts as referral
adult Medical Centre for all western Sicily (Italy), con-
sidered an endemic area for VL. Fifty-five apparently
immunocompetent, HIV-negative patients, clinically
healed after an effective treatment of an acute episode of
VL, were examined over a 14 years period (January 1992–
December 2006) for serum IgG antibodies to L. infantum.
The samples were collected during the acute phase of the
disease (basal), every 6 months for the first year after the
treatment and every 12 months for the subsequent 14 years
after the treatment. All patients were also submitted to
clinical examination.
We also examined the persistence and kinetic of serum
IgG antibodies to L. infantum in 2 patients with a diagnosis
of VL relapse and 2 with resistance to specific therapy.
Whole blood (5 ml) was collected into sterile tubes at
the acute phase stage and at the follow-up stage. Blood was
allowed to coagulate for 2–3 h at 4C prior to centrifuga-
tion. Serum samples were preserved at -20C until
analysis.
Diagnosis of acute VL was based on clinical symptoms,
such as persistent irregular fever, pallor, weight loss,
hepatosplenomegaly, anemia, neutropenia, thrombocyto-
penia, hypergammaglobulinemia, and was confirmed by
the presence of antibodies against L. infantum, detected by
IFAT, and of L. infantum bodies in bone marrow aspirates
and/or biopsy, and in some cases, also with parasites iso-
lation and culture from bone marrow aspirates and/or
biopsy, and/or from peripheral blood. VL patients were
treated with a complete course of meglumine antimoniate
(MA, 20 mg/kg daily, by intramuscular injection, for
4 weeks) [9, 14] or liposomal amphotericin B (1–3 mg/kg
daily, for 5 days, with a final dose at 11th day, with no
incremental dosage, infused slowly over 2 h). Patients were
considered cured and discharged when fever subsided, and
there was weight gain and absence of L. infantum bodies in
the bone marrow aspirates and/or biopsy. By these criteria,
all the patients were considered clinically cured. During the
follow-up period, none of the examined patients showed
signs or symptoms of active disease. VL relapse was
defined by the recurrence of a clinical and parasitological
(i.e., stained preparations from bone marrow aspirate and/
or biopsy) diagnosis of L. infantum infection, after specific
treatment of the disease [15].
Informed, written consent from all participants and the
approval of the ethical committee of our institution were
obtained for this study.
IFAT for L. infantum
All sera were analyzed by IFAT, using ‘‘in-house antigen’’
to increase tests sensitivity [16].
In details, promastigotes of L. infantum (zymodeme
MON-1), previously isolated from a VL patient, identified
as L. infantum, and then cultivated in our laboratory, were
propagated in Medium 199 (Gibco, Milan, Italy), supple-
mented with 25 mM Hepes (Gibco, Milan, Italy) and 10%
fetal calf serum (Gibco, Milan, Italy). After 48 h of incu-
bation at 27C, whole parasites were collected by centri-
fugation, washed three times in cold phosfate-buffered
saline (PBS, Bio-Merieux, Rome, Italy), and then fixed on
slides (Bio-Merieux, Rome, Italy), until to obtain 30–40
parasites for microscopic field. Anti-L. infantum serum-
specific IgG antibodies were then evaluated as previously
described [17, 18].
The lower limit of positivity (cut-off) has been set to
discriminate optimally between sera of clinical docu-
mented cases of VL and normal human sera. All samples
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showing a titer at a dilution C1:100 were considered to be
positive.
To ensure comparable results over more than 10 years,
we tested all the samples with the same antigen batch, and
the assays were carried out by the same operator.
Results
Of the 55 patients studied, 67% were men (mean age
45 ± 11, range 16–85 years) and 33% were women (mean
age 32 ± 9, range 22–63 years). Twelve were treated with
MA and 33 with liposomal amphotericin B.
In Fig. 1 is reported the box plot analysis of the kinetic
of specific IgG antibodies to L. infantum, examined in
different periods of time, after the onset of acute VL, in
cured and apparently healed subjects. To linearize the
relation between time and results, we expressed them in a
logarithmic scale. After acute VL and VL-specific treat-
ment, serum-specific IgG antibodies titers, detected in the
100% of the examined cases during the acute phase of the
disease, decreased slowly, but constantly, from a seropos-
itivity of 98.1% at 6 months to a seropositivity of 16.3% at
72 months. During the follow-up, antibodies to L. infantum
persisted mainly at low levels (from 1:100 to 1:200) until
their disappearance in 4–6 years. In 8 patients (14.5%),
specific antibodies to L. infantum were detected even after
14 years after acute VL and VL-specific treatment, at low-
medium titers (from 1:100 to 1:1,600), without any
symptoms/signs of persistent or relapsing VL.
In Table 1, we showed the anti-L. infantum antibodies
kinetic of 2 patients with a diagnosis of VL relapse and 2
with a diagnosis of resistance to specific therapy. The first
two patients (no. 1 and no. 2) had a clinically and parasi-
tological confirmed relapse of VL, probably due to an
inadequate anti-Leishmania therapy, carried out in other
hospitals. In these two patients, clinically cured after the
first cycle of treatment, the kinetic of specific antibodies to
L. infantum was characterized by an initial reduction, after
the first VL episode, and a subsequent antibody levels
increase 12 and 24 months afterward, respectively, con-
sistent to a sentinel epiphenomenon of a contemporary
clinically and parasitological confirmed VL recurrence. We
successfully treated both patients with liposomal ampho-
tericin B. After these therapy cycles, the antibody titers
decreased under the cut-off level, remaining negative
during a 6 years follow-up. The other two patients (no. 3
and no. 4) had a clinical and parasitological diagnosis of
VL not responding to specific therapy, and persistent high
levels of antibodies to L. infantum, as expression of resis-
tance to therapy. Then, the patients were successfully
treated with liposomal amphotericin B and antibody levels
reduced significantly in a few months, until to disappear,
persisting at negative titer in the following 6 years.
Discussion
Based on the results of our study, patients specifically
cured and apparently healed after an acute episode of VL
could be divided into three subtypes of antibody response:
(1) patients whose anti-L. infantum antibodies disappear
within 2 years after diagnosis and treatment, as just
reported in the literature [7–13]; (2) patients showing low
antibody titers for 4–6 years; and (3) patients whose anti-
body titers remain constantly at low-medium levels for
more than 6 years.
Considering our cases of VL relapse and resistance to
specific therapy, it is possible to hypothesize that moni-
toring of L. infantum antibody levels, both in case of acute
and not apparently motivated increase of antibody levels
and of persistence of high antibody levels, respectively,
might be useful for a better definition of these two condi-
tions. However, other studies are required, with more
patients and adequate controls.
In few patients (8 of 55, 14.5%), we found detectable, at
low-medium concentrations (from 1:100 to 1:1,600), serum
IgG antibodies to L. infantum after more than 72 months
(up to 14 years after acute VL and specific VL treatment).
In all these subjects, we did not diagnose a relapsing dis-
ease or a resistance to specific therapy. However, the eth-
ical committee of our institution did not consider ethically
acceptable to submit these apparently seropositive healthy
Fig. 1 Box plot analysis of the kinetic of specific IgG antibodies to L.
infantum, examined in different periods of time, after the onset of
acute VL, in cured and apparently healed subjects. Titres are
expressed in logarithmic scale. The results represented by ‘‘*’’ are
anomoly in the statistical analysis and they are not cinsidered in box
plot elaboration [27]. The last box because of scantly number of cases
should not be considered, even if the trend of population is not
different from the previous one
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subjects to a bone marrow aspirate and/or biopsy to detect a
possible, criptic, L. infantum infection.
The biologic significance of persistent serum IgG anti-
bodies to L. infantum in patients cured and apparently
healed form VL is still unclear. One explanation might be
that individuals with VL do not show complete elimination
of the parasite. This agrees with the opportunistic occur-
rence of the diseases, as observed in patients with AIDS
[19–25].
We think that positive serologic results in patients
treated for VL, and apparently healed, did not indicate poor
therapeutic response or prognosis. In this contest, some
studies have demonstrated that serological tests for VL
(i.e., ELISA using rK39, rK26, and crude Leishmania
antigen) in VL patients after clinical cure might continue to
be positive after treatment of the disease and cannot be
used as an indicator of an adverse therapeutic and prog-
nostic evolution [9, 26].
Even though other studies have demonstrated the per-
sistence of antibodies to L. infantum for long time, this is
the first report showing a persistence of them up to
14 years. The principal limitation of our research is the few
patients studied, but it is important to consider that the
disease is not particularly frequent in our geographic area
[2].
In conclusion, our results, confirming and extending
previous studies [7–13], showed that specific antibodies to
L. infantum might persist for many years, and decrease
slowly, but steadily. The persistence of these specific
antibodies, at low-medium levels, is not related to poor
therapeutic response or prognosis, but an acute increase in
their levels, or the persistence of high antibody levels,
might be useful in identifying LV relapse or resistance to
specific therapy.
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